Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 8/20 | 0.51 |
| ▸ | ATP1B1 | P05026 | 8/20 | 0.51 |
| ▸ | ATP1A3 | P13637 | 8/20 | 0.51 |
| ▸ | ATP1B2 | P14415 | 8/20 | 0.51 |
| ▸ | ATP1A2 | P50993 | 8/20 | 0.51 |
| ▸ | ATP1B3 | P54709 | 8/20 | 0.51 |
| ▸ | FXYD2 | P54710 | 8/20 | 0.51 |
| ▸ | ATP1A4 | Q13733 | 8/20 | 0.51 |
| ▸ | TP53 | P04637 | 9/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | STAT3 | P40763 | 2/20 | 0.49 |
| ▸ | SLCO4C1 | Q6ZQN7 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 4/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL2960997 | 0.99 | ATP1A1 (0.50) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL8830696 | 0.92 | TP53 (0.56) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL8830484 | 0.92 | TP53 (0.56) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL11211273 | 0.83 | ATP1A1 (0.53) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL11207874 | 0.82 | ATP1A1 (0.52) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL7309200 | 0.82 | TP53 (0.68) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL8999665 | 0.82 | TP53 (0.68) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL11654361 | 0.82 | TP53 (0.68) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL7279420 | 0.82 | TP53 (0.68) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL11806297 | 0.82 | TP53 (0.68) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507411-B2 | Neoglycorandomization and digitoxin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-08-13 | — | — | US | disclosed |
| US-8344133-B2 | Neoglycorandomization and digitoxin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100256078-A1 | NEOGLYCORANDOMIZATION AND DIGITOXIN ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7754874-B2 | Have significantly enhanced cytotoxic potency toward human cancer cells and tumor-specificity, are less potent Na+/K+-ATPase inhibitors in a human cell line than digitoxin | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090075842-A1 | NEOGLYCORANDOMIZATION AND DIGITOXIN ANALOGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-19 | — | — | US | disclosed |
| EP-1768992-A1 | NEOGLYCORANDOMIZATION AND DIGITOXIN ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060041109-A1 | Neoglycorandomization and digitoxin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-02-23 | — | — | US | disclosed |
| WO-2006002381-A1 | NEOGLYCORANDOMIZATION AND DIGITOXIN ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041109-A1 | Neoglycorandomization and digitoxin analogs | CANX, DERA, GALE | ATP1A1 44/4885ATP1B1 24/4885ATP1A3 35/4885 |
| US-20090075842-A1 | NEOGLYCORANDOMIZATION AND DIGITOXIN ANALOGS | CANX, DERA, GALE | ATP1A1 44/4885ATP1B1 24/4885ATP1A3 35/4885 |
| US-20100256078-A1 | NEOGLYCORANDOMIZATION AND DIGITOXIN ANALOGS | CANX, DERA, GALE | ATP1A1 44/4885ATP1B1 24/4885ATP1A3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.